ALKSMEDIUM SIGNALFINANCIAL10-K

ALKS significantly increased share buybacks to $200.3M while R&D spending jumped 32.1%, but operating income declined 39.6% despite strong balance sheet growth.

The company appears to be in a reinvestment phase, ramping up R&D spending substantially while returning significant cash to shareholders through buybacks. The decline in operating income amid higher R&D costs suggests ALKS is prioritizing pipeline development over near-term profitability, which could signal confidence in future revenue opportunities or pressure on current product performance.

Comparing 2026-02-25 vs 2025-02-12View on EDGAR →
FINANCIAL ANALYSIS

ALKS demonstrated strong balance sheet expansion with total assets growing 21% to $2.5B and cash increasing 33.5% to $388.6M, while stockholders equity rose 24.2%. However, profitability metrics declined significantly with operating income falling 39.6% and net income dropping 34.2%, primarily driven by a 32.1% increase in R&D expenses to $324M. The dramatic increase in share buybacks from $2.7M to $200.3M indicates aggressive capital allocation to shareholders despite reduced earnings, suggesting management confidence in the business despite near-term profit pressures.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+7362.1%
$2.7M$200.3M

Share repurchases increased 7362.1% — management returning capital, signals confidence in intrinsic value.

Interest Expense
P&L
+76.6%
$13.0M$23.0M

Interest expense surged 76.6% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-39.6%
$420.6M$254.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
+36.3%
$1.4B$1.9B

Current assets grew 36.3% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
-34.2%
$367.1M$241.7M

Net income declined 34.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+33.5%
$291.1M$388.6M

Cash position surged 33.5% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
+32.1%
$245.3M$324.0M

R&D investment increased 32.1% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
+24.2%
$1.5B$1.8B

Equity base grew 24.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+21%
$2.1B$2.5B

Asset base grew 21% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
+20.7%
$33.5M$40.4M

Capex increased 20.7% — ongoing investment in capacity or infrastructure for future growth.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-12
ADDED
As of February 20, 2026, 166,649,934 ordinary shares were outstanding.
Securities and Exchange Commission ( SEC ) and other government agencies could negatively impact our business; we may not be able to successfully expand our research and development ( R D ) pipeline or our commercial product portfolio, which could limit our growth potential; we are subject to risks related to the manufacture of our products; we rely on third parties to provide goods and services in connection with the manufacture and distribution of our products; LUMRYZ is a controlled substance subject to U.S.
government or governments of other nations, could have an adverse effect on our business, results of operations, or financial condition.
); ANTABUSE Teva Women s Health, Inc.; AUBAGIO and LEMTRADA Sanofi Societe Anonyme France; AVONEX , PLEGRIDY , TECFIDERA , TYSABRI and VUMERITY Biogen MA Inc.
(together with its affiliates, Biogen ); BETASERON Bayer Pharma AG; BRIXADI Braeburn Inc.; BRIUMVI TG Therapeutics, Inc.; BUNAVAIL TM BioDelivery Sciences; CAMPRAL Merck Sante;COPAXONE and UZEDY Teva Pharmaceutical Industries Ltd.
+7 more — sign up free →
REMOVED
As of February 7, 2025, 162,614,067 ordinary shares were outstanding.
federal and Irish tax purposes as we anticipate, we and/or our shareholders could be subject to significant tax liabilities; 4 the market price of our ordinary shares has been volatile and may continue to be volatile in the future, and could decline significantly; our business could be negatively affected as a result of the actions of activist shareholders; and information security breaches and other disruptions could compromise our information and expose us to liability, which could cause our business and reputation to suffer.
( Acorda ); ANJESO Baudax Bio, Inc.; ANTABUSE Teva Women s Health, Inc.; AUBAGIO and LEMTRADA Sanofi Societe Anonyme France; AVONEX , PLEGRIDY , TECFIDERA , TYSABRI and VUMERITY Biogen MA Inc.
(together with its affiliates, Biogen ); BETASERON Bayer Pharma AG; BRIXADI Braeburn Inc.; BRIUMVI TG Therapeutics, Inc.; BUNAVAIL TM BioDelivery Sciences; CAMPRAL Merck Sante; CAPLYTA Intra-Cellular Therapies, Inc.; COPAXONE and UZEDY Teva Pharmaceutical Industries Ltd.
Lundbeck A/S plc; PERSERIS , SUBOXONE , SUBUTEX and SUBLOCADE Indivior plc (or its affiliates); RYKINDO Luye Pharma Group; VRAYLAR Forest Laboratories, LLC; COBENFY and ZEPOSIA Bristol-Myers Squibb Company; ZUBSOLV Orexo US, Inc.; and ZYPREXA and ZYPREXA RELPREVV Eli Lilly and Company ( Lilly ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →